Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mass. Medicaid Leukotriene Blocker Limitation Seeks To Curb Allergy Use

Executive Summary

Oral leukotriene blocker prescriptions will require prior authorization in the Massachusetts Medicaid program in an effort to curb use of the products for allergic rhinitis

You may also be interested in...



Mass. Medicaid To Establish Quantity Limit For Short-Acting Beta-2 Agonists

Massachusetts Medicaid will establish a quantity limit for short-acting beta-2 agonists to encourage physicians to alter "inadequate" anti-inflammatory therapy

Mass. Medicaid To Establish Quantity Limit For Short-Acting Beta-2 Agonists

Massachusetts Medicaid will establish a quantity limit for short-acting beta-2 agonists to encourage physicians to alter "inadequate" anti-inflammatory therapy

Merck Singulair Formulary Status Stable; Restricted Use In Subset Of Plans

Merck's Singulair allergic rhinitis indication is gaining formulary status in the majority of managed care accounts despite the availability of OTC Claritin, the company told investors April 21

Related Content

UsernamePublicRestriction

Register

PS041739

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel